PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 2, 2017Applied immunohistochemistry & molecular morphology71 citations

Phosphorylated Histone H3 (PHH3) as a Novel Cell Proliferation Marker and Prognosticator for Meningeal Tumors: A Short Review

View Full Paper
İEİlhan ElmacıMAMeriç A. AltinozRSRamazan Sarı

Key Points

Key points are not available for this paper at this time.

Abstract

Cell proliferation markers are used in grading of brain tumors and in patient stratification for different treatments. Therefore, defining simple and accurate proliferation markers are of essential importance. Ki67 labeling index is widely studied, yet it is subject to interlaboratory variability. Ki67 protein is expressed on all cell cycle phases except G0 and does not precisely reflect proliferating cells. Counting mitotic figures (MFs) is used in World Health Organization grading of brain tumors (meningiomas), but the detection of MFs on conventional hematoxylin and eosin stained slides is very time consuming. Further, karyorrhexis and pyknosis in apoptotic or crushed cells may mimic mitotic morphology and falsify counting results. Histone H3 phosphorylation on serine-10 is specific to mitosis and phosphorylated histone H3 (PHH3) proliferation markers (as counts defined per area or as indices defined per cell numbers) are increasingly being used to evaluate proliferation in various tumors. Herein, we review current data on PHH3 proliferation markers in meningeal tumors. PHH3-staining highlights mitotic cells and makes easier of rapid grading by driving pathologist's attention on the most mitotically active areas. Thereby, it would function more sensitive in detecting MFs that might be otherwise overloked and more precise by reducing interobserver variability through allowing the pathologist to analyze if the stained nuclei exhibit morphologic features of mitosis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Elmacı et al. (2017) studied this question.

synapsesocial.com/papers/69d7793f3fae90fd6048f3eehttps://doi.org/10.1097/pai.0000000000000499
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phosphohistone H3: implications for clinical practice and risk assessment in meningioma2015 · 9 citations
  2. 2The Utility of MIB-1/Ki-67 Immunostaining in the Evaluation of Central Nervous System Neoplasms2005 · 55 citations
  3. 3PCNA and Ki-67 in Central Nervous System Tumors: Correlation with the Histological Type and Grade2002 · 92 citations
  4. 4Positivity of the Proliferation Marker Ki-67 in Noncycling Cells1998 · 144 citations
  5. 5The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria2004 · 147 citations